Home | Corporate Website | Joint Care | Contact Us

Clinical Studies for Trimma ingredients

trimma is a dual-action appetite and weight control system combining clinically-tested Slendesta^® and PinnoThin™.

Clinical Study Overview Eleven clinical studies with over 500 participants, collectively, have demonstrated Slendesta®'s benefits, including that it is a safe and effective natural ingredient that promotes satiety and healthy weight loss. When taken as directed, Slendesta® has resulted in statistically significant weight loss and reductions in waist and hip measurements. A randomized placebo controlled, crossover clinical study with 45 participants demonstrated that Slendesta® taken before a meal results in significantly greater fullness and decreased motivation to eat. This study also showed that the CCK levels were significantly increased and remained elevated for a longer period of time post meal than the placebo group. In the largest randomized, double-blind controlled clinical study, 240 participants consumed Slendesta® approximately 60 minutes before the two largest meals. Results showed statistically significant reductions in weight, waist and hips. An open label study for a total of 20 weeks, participants lost an average of 0.6 lbs per week and had statistically significant reductions of 16% (6.3 inches) in waist and 9% (4 inches) in hip. Click here to view a PDF of the studies.

Clinical Study Overview The appetite-suppressing effect of PinnoThin™ was evaluated in a randomized, double blind, placebo-controlled, cross-over human trial. The trial was performed by a renowned research institute, TNO, in the Netherlands. Eighteen overweight but otherwise healthy, middle-aged women participated in this study. They were given a simple breakfast consisting of two slices of white bread and marmalade, along with three grams of PinnoThin™ or three grams of placebo (olive oil). The women were monitored up to four hours after the breakfast. Both CCK and GLP1 release in the blood was measured 30, 60, 90, 120, 180 and 240 minutes after the start of the breakfast. Each subject completed both interventions (PinnoThin™ and placebo) with a 1 week wash-out between them. The study showed a clear increase in CCK release after PinnoThin™ consumption when compared to the placebo. The effect on CCK release became apparent after 30 minutes and lasted for three hours (Figure 2). GLP1 release was also increased after PinnoThin™ consumption as compared to the placebo. An effect on GLP1 release was observed after 60 minutes and lasted again for three hours. Click here to view a PDF of the study.